Pulmonx Corp (LUNG) FinancialsLUNGPulmonx Corp

Evaluating the bottom line, Pulmonx Corp maintains a gross margin of 77.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -39.80%, while the net margin is -44.30%. These profitability ratios, combined with a Return on Equity (ROE) of -88.87%, provide a clear picture of how effectively LUNG converts its operational activities into shareholder value.

In the context of the broader market, LUNG competes directly with industry leaders such as LNSR and WRAP. With a market capitalization of $102.22M, it holds a significant position in the sector. When comparing efficiency, LUNG's gross margin of 77.97% stands against LNSR's 57.88% and WRAP's 75.29%. Such benchmarking helps identify whether Pulmonx Corp is trading at a premium or discount relative to its financial performance.

Pulmonx has demonstrated a gross margin of 77.97% in Q2 2026, an increase from previous quarters, indicating effective cost management despite revenue challenges. The company reported a net loss of $10.1 million, a significant improvement from prior losses, reflecting a narrowing trend in losses over time.